ArticleActa pharmacologica Sinica2018
3-Acetyl-oleanolic acid ameliorates non-alcoholic fatty liver disease in high fat diet-treated rats by activating AMPK-related pathways.
Article in Acta pharmacologica Sinica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Computational Network Pharmacology, Molecular Docking, and Molecular Dynamics to Decipher Natural Compounds ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Current Progress of Hederagenin and Its Derivatives for Disease Therapy (2017-Present).Molecules (Basel, Switzerland) · 2025Review
- Therapeutic potential of oleanolic acid in liver diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Oleanolic acid improved intestinal immune function by activating and potentiating bile acids receptor signaling in E. coli-challenged piglets.Journal of animal science and biotechnology · 2024Article
- Integrating network pharmacology with molecular docking to rationalize the ethnomedicinal use ofFrontiers in pharmacology · 2024Article
- Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD.International journal of molecular sciences · 2023Review
- Metformin induces pyroptosis in leptin receptor-defective hepatocytes via overactivation of the AMPK axis.Cell death & disease · 2023Article
- Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy.Molecules (Basel, Switzerland) · 2022Review
- Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drugActa pharmaceutica Sinica. B · 2022Review
- Naoxintong Capsule Alternates Gut Microbiota and Prevents Hyperlipidemia in High-Fat-Diet Fed Rats.Frontiers in pharmacology · 2022Article
- Ablation of Akt2 and AMPKActa pharmaceutica Sinica. B · 2021Article
- Article
- Epac1 Requires AMPK Phosphorylation to Regulate HMGB1 in the Retinal Vasculature.Investigative ophthalmology & visual science · 2020Article
- Prophylactic and therapeutic roles of oleanolic acid and its derivatives in several diseases.World journal of clinical cases · 2020Review
- Hepatitis C virus nonstructural protein 5A perturbs lipid metabolism by modulating AMPK/SREBP-1c signaling.Lipids in health and disease · 2019Article
- Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.World journal of gastroenterology · 2019Article
- Plant-derived oleanolic acid ameliorates markers associated with non-alcoholic fatty liver disease in a diet-induced pre-diabetes rat model.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Apoptosis and non-alcoholic fatty liver diseases.World journal of gastroenterology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3-Acetyl-oleanolic acid (3Ac-OA) is a derivative of oleanolic acid (OA), which has shown therapeutic beneficial effects on diabetes and metabolic syndrome. In this study we investigated whether 3Ac-OA exerted beneficial effect on non-alcoholic fatty liver disease (NAFLD) in rats and its potential underlying mechanisms. Treatment with 3Ac-OA (1-100 μmol/L) dose-dependently decreased the intracellular levels of total cholesterol (TC) and triglyceride (TG) in FFA-treated primary rat hepatocytes and human HepG2 cell lines in vitro. Furthermore, oil red staining studies showed that 3Ac-OA caused dose-dependent decrease in the number of lipid droplets in FFA-treated primary rat hepatocytes. SD rats were fed a high fat diet (HFD) for 6 weeks and subsequently treated with 3Ac-OA (60, 30, 15 mg·kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.